Products and Services

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing… Read more . . .

CDMO Intertek has announced an expansion of a GMP stability storage facility near Cambridge, UK, noting that the expanded facility offers custom temperature and relative humidity conditions and is suitable for stability testing of a… Read more . . .

 Copley Scientific has announced the launch of its SRS 100i automated sample recovery system for use with delivered dose uniformity and APSD testing set-ups, including the compendial dose uniformity sample apparatus (DUSA), the Next Generation Impactor (NGI),… Read more . . .

Rocket Science Health announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,569,658, titled “Dual Nozzles For Insertion Into Paired Body Orifices (e.g., Nasal Passages, Etc.)” covering the company’s intranasal… Read more . . .

Device company Nemera and UK-based pharma company Therakind have announced a deal that will allow Nemera to add Therakind’s DriDose intranasal dry powder delivery technology to its portfolio. Therakind, which is developing several nasal DPI products… Read more . . .

CDMO Experic and particle engineering specialist Flurry Powders have announced a partnership to offer development services for inhaled and nasal drug formulations that require specialized particle engineering and manufacturing. The companies cite potential opportunities for dry… Read more . . .

Zydus Lifesciences has announced the launch of a foldable MDI spacer after acquiring marketing and commercialization rights to the device from Mumbai-based AeroDel Technology Innovations. The spacer, which AeroDel calls A202, is being marketed by… Read more . . .

Australian biopharm Covirix Medical, which is developing a broad-spectrum antiviral, has signed a letter of intent with Aptar Pharma  for a feasibility study evaluating delivery of the antiviral via Aptar’s Orbital dry powder inhaler. The… Read more . . .